Anaphylaxis, Dose-Ranging Hurdles May Trip Teva's Reslizumab
This article was originally published in Scrip
Even though GlaxoSmithKline PLC's recently approved Nucala (mepolizumab) – the first anti-interleukin-5 (IL-5) treatment in the US for adults and adolescents with severe asthma with an eosinophilic phenotype – has paved the way for Teva Pharmaceutical Industries Ltd.'s reslizumab, when the latter drug goes before an advisory committee later this week, it must clear its own hurdles, which includes anaphylaxis and muscle toxicity, along with limited dose-ranging data, which may trip up the experimental medicine in the end.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.